Notice of Application Due Date Changes for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)"
Notice Number:
NOT-HL-22-017

Key Dates

Release Date:

March 24, 2022

Related Announcements

RFA-HL-23-010 - Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

RFA-HL-23-011 - Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)

RFA-HL-23-012 - Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

RFA-HL-23-013 - Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)

RFA-HL-23-014 - Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)

NOT-HL-22-015 - Notice of Application Submission and Due Date Changes for RFA-HL-23-010, "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)"

NOT-HL-22-016- Notice of Application Due Date Changes for RFA-HL-23-011,"Catalyze:Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)"

NOT-HL-22-018 - Application Due Date Changes for RFA-HL-23-013, "Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)"

NOT-HL-22-019 - Application Due Date Changes for RFA-HL-23-014, "Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33)"

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to alert potential applicants to a change in key dates for RFA-HL-23-012, "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)". Changes are shown in bold italics below.

Current dates:

Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date
March 21, 2022 March 21, 2022 April 18, 2022 July 1, 2022 October 1, 2022 December 1, 2022
July 21, 2022 July 21, 2022 August 18, 2022 November 1, 2022 January 1, 2023 April 1, 2023
November 21, 2022 November 21, 2022 December 21, 2022 March 1, 2023 May 1, 2023 July 1, 2023
March 21, 2023 March 21, 2023 April 18, 2023 July 1, 2023 October 1, 2023 December 1, 2023
July 21, 2023 July 21, 2023 August 18, 2023 November 1, 2023 January 1, 2024 April 1, 2024
November 21, 2023 November 21, 2023 December 21, 2023 March 1, 2024 May 1, 2024 July 1, 2024
March 21, 2024 March 21, 2024 April 18, 2024 July 1, 2024 October 1, 2024 December 1, 2024
July 21, 2024 July 21, 2024 August 18, 2024 November 1, 2024 January 1, 2025 April 1, 2025
November 21, 2024 November 21, 2024 December 20, 2024 March 1, 2025 May 1, 2025 July 1, 2025


Revised dates (in bold italics):

Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date
March 21, 2022 March 21, 2022 April 18, 2022 July 1, 2022 October 1, 2022 December 1, 2022
July 21, 2022 July 21, 2022 August 18, 2022 November 1, 2022 January 1, 2023 April 1, 2023
November 21, 2022 November 21, 2022 December 21, 2022 March 1, 2023 May 1, 2023 July 1, 2023
February 21, 2023 February 21, 2023 April 18, 2023 July 1, 2023 October 1, 2023 December 1, 2023
July 21, 2023 July 21, 2023 August 18, 2023 November 1, 2023 January 1, 2024 April 1, 2024
November 21, 2023 November 21, 2023 December 21, 2023 March 1, 2024 May 1, 2024 July 1, 2024
February 21, 2024 February 21, 2024 April 18, 2024 July 1, 2024 October 1, 2024 December 1, 2024
July 22, 2024 July 22, 2024 August 19, 2024 November 1, 2024 January 1, 2025 April 1, 2025
November 21, 2024 November 21, 2024 December 20, 2024 March 1, 2025 May 1, 2025 July 1, 2025


All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Mike Pieck, Ph.D.
Telephone: 301-827-7986
Email: nhlbi_catalyze@nih.gov